Is The IRA’s Impact On Innovation Being Overstated?

With the passage of the Inflation Reduction Act, many have questioned whether Medicare price negotiations will stifle small molecule innovation.

Will The Inflation Reduction Act Stifle Small Molecule Innovation As Some Believe? • Source: Shutterstock

Since President Biden signed the Inflation Reduction Act into law on 16 August 2022, the biopharma industry has been in a state of collective agitation and unrest. The IRA’s Medicare Drug Price Negotiation section allows Medicare to negotiate directly with drug companies for branded drugs covered under Medicare Part B and Part D. Now less than two years away from the first 10 Part D drug limits being implemented and four years away from the first batch of Part B drugs, industry-wide debate continues as to whether the IRA will significantly stifle innovation, particularly for small molecules, or whether it will be nothing more than a necessary part of doing business in the US.

Under the IRA, small molecule drugs without generic competition that are in the top 50 in terms of Medicare spending...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By 

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.